查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591977

免疫查核點抑制劑市場：按類型、適應症、給藥途徑、最終用戶、分銷管道 - 全球預測 2025-2030

Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Route of Administration, End-Users, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

免疫查核點抑制劑市場2023年估值為94.7億美元，預計2024年將達到104.6億美元，複合年成長率為10.82%，到2030年將達到194.6億美元。

免疫查核點抑制劑市場的範圍和定義圍繞著旨在幫助免疫系統更有效地識別和攻擊癌細胞的藥物。這些抑制劑以 PD-1、PD-L1 和 CTLA-4 等蛋白質為目標，通常會抑制免疫系統的活動，使其不會攻擊癌細胞。越來越多的癌症（包括黑色素瘤、肺癌和腎癌）推動了對這些抑制劑的需求，這些癌症需要比傳統化療和放射線治療更有效的治療方法。免疫查核點抑制劑療法主要針對腫瘤學，為免疫療法治療癌症帶來新的希望。最終用途範圍包括醫院、癌症研究機構和專科診所，這些藥物主要在這些地方進行管理和研究。

主要市場統計
基準年[2023] 94.7億美元
預測年份 [2024] 104.6億美元
預測年份 [2030] 194.6億美元
複合年成長率（%） 10.82%

根據市場洞察，生物技術的進步、新藥的監管核准以及癌症研究投資的增加是關鍵的成長要素。市場正在見證透過可以提高治療效果的個人化醫療和聯合治療的成長機會。對企業來說，與研究機構合作、投資臨床試驗是抓住新機會的途徑。然而，治療成本高、潛在副作用和患者反應有限等限制因素給市場擴張帶來了挑戰。來自其他治療方法的監管障礙和競爭壓力也構成了威脅。

創新的可能性包括探索非腫瘤應用、增強遞送機制和減少副作用，這可能開闢新的途徑。研究預測生物標記以確定可能對治療有反應的患者可以顯著最佳化治療結果。儘管本質上競爭激烈，但該市場為旨在改善患者特異性治療策略和擴大治療覆蓋範圍的創新提供了肥沃的土壤。鑑於進展速度之快，研發方面的策略聯盟和合作對於持續成長和競爭優勢至關重要。

市場動態：快速發展的免疫查核點抑制劑市場的關鍵市場洞察

免疫查核點抑制劑市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症盛行率不斷上升
    • 政府不斷加強癌症治療和意識提升計劃
    • 老年人口不斷成長，生活方式不健康
  • 市場限制因素
    • 對免疫查核點抑制劑的副作用、高成本和療效的擔憂
  • 市場機會
    • 先進癌症治療的持續研究活動
    • 新型免疫查核點抑制劑的監管核准增加
  • 市場挑戰
    • 癌症替代治療方法的存在

波特五力：駕馭免疫查核點抑制劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解免疫查核點抑制劑市場的外部影響

外部宏觀環境因素在塑造免疫查核點抑制劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解免疫查核點抑制劑市場的競爭格局

對免疫查核點抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣免疫查核點抑制劑市場供應商的績效評估

FPNV 定位矩陣是評估免疫查核點抑制劑市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了免疫查核點抑制劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，免疫查核點抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率增加
      • 政府加大對癌症治療和宣傳計劃的承諾
      • 老年人口不斷增加，生活方式不健康
    • 抑制因素
      • 對免疫查核點抑制劑的相關副作用、高成本和功效的擔憂
    • 機會
      • 正在進行的先進癌症治療研究活動
      • 新型免疫查核點抑制劑的監管核准增加
    • 任務
      • 癌症替代治療方法的存在
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章免疫查核點抑制劑市場：依類型

  • CTLA-4抑制劑
  • PD-1抑制劑
  • PD-L1抑制劑

第7章依適應症分類的免疫查核點抑制劑市場

  • 膀胱癌
  • 乳癌
  • 子宮頸癌
  • 何傑金氏淋巴瘤
  • 腎癌
  • 肝癌
  • 肺癌
  • 固體癌

第8章免疫查核點抑制劑市場：依給藥途徑

  • 口服
  • 胃腸外的

第9章免疫查核點抑制劑市場：依最終用戶分類

  • 醫院
  • 專科診所

第10章免疫查核點抑制劑市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲免疫查核點抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太免疫查核點抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲免疫查核點抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alphamab Oncolog
  • ALX Oncology Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • ImmuneSensor Therapeutics Inc.
  • ImmunityBio, Inc.
  • Kintor Pharmaceutical Limited
  • Merck KGaA
  • MiNK Therapeutics, Inc.
  • NATCO Pharma Ltd.
  • NextCure, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Seagen Inc.
  • SQZ Biotechnologies Company
  • Thermo Fisher Scientific Inc.
  • Xencor, Inc.
Product Code: MRR-FF012EDC38BE

The Immune Checkpoint Inhibitors Market was valued at USD 9.47 billion in 2023, expected to reach USD 10.46 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 19.46 billion by 2030.

The scope and definition of the immune checkpoint inhibitors market revolve around drugs designed to help the immune system recognize and attack cancer cells more effectively. These inhibitors target proteins, such as PD-1, PD-L1, and CTLA-4, which typically suppress immune system activity to prevent it from attacking cancer cells. The necessity for these inhibitors is driven by the increasing prevalence of various cancers, including melanoma, lung, and renal cancers, that require more effective treatment options beyond traditional chemotherapy and radiation. Applications of immune checkpoint inhibitors are largely focused on oncology, providing new hope in immunotherapy for cancer treatment. The end-use scope includes hospitals, cancer research institutes, and specialty clinics, where these drugs are predominantly administered and studied.

KEY MARKET STATISTICS
Base Year [2023] USD 9.47 billion
Estimated Year [2024] USD 10.46 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 10.82%

Market insights reveal that significant growth factors include advancements in biotechnology, approval of new drugs by regulatory bodies, and increasing investments in cancer research. The market is witnessing growth opportunities through personalized medicine and combination therapies, which can enhance treatment efficacy. For businesses, collaborating with research institutions and investing in clinical trials offer ways to seize emerging opportunities. However, limitations such as high treatment costs, potential adverse effects, and limited patient response challenge market expansion. Regulatory hurdles and competitive pressures from other treatment modalities also pose threats.

For innovative potential, exploring non-oncological applications, enhancing delivery mechanisms, and reducing adverse effects can pave new paths. Research into predictive biomarkers to identify patients most likely to respond to therapy can significantly optimize treatment outcomes. The market is inherently competitive but provides fertile ground for innovation aimed at improving patient-specific treatment strategies and broadening therapeutic applicability. Given the rapid pace of advancements, strategic alliances and collaborations in research and development will be crucial for sustained growth and gaining a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immune Checkpoint Inhibitors Market

The Immune Checkpoint Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer across the globe
    • Rising government initiatives for cancer treatment and awareness programs
    • Growing geriatric population and adoption of unhealthy lifestyle
  • Market Restraints
    • Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
  • Market Opportunities
    • Ongoing research activities for advanced cancer treatments
    • Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
  • Market Challenges
    • Presence of alternative treatment therapies for cancer

Porter's Five Forces: A Strategic Tool for Navigating the Immune Checkpoint Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immune Checkpoint Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immune Checkpoint Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immune Checkpoint Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immune Checkpoint Inhibitors Market

A detailed market share analysis in the Immune Checkpoint Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immune Checkpoint Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immune Checkpoint Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immune Checkpoint Inhibitors Market

A strategic analysis of the Immune Checkpoint Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alphamab Oncolog, ALX Oncology Inc., Astellas Pharma Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., Kintor Pharmaceutical Limited, Merck KGaA, MiNK Therapeutics, Inc., NATCO Pharma Ltd., NextCure, Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Seagen Inc., SQZ Biotechnologies Company, Thermo Fisher Scientific Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor.
  • Based on Indication, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Hodgkin Lymphoma, Kidney Cancer, Liver Cancer, Lung Cancer, and Solid Cancer.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on End-Users, market is studied across Hospitals and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer across the globe
      • 5.1.1.2. Rising government initiatives for cancer treatment and awareness programs
      • 5.1.1.3. Growing geriatric population and adoption of unhealthy lifestyle
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities for advanced cancer treatments
      • 5.1.3.2. Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of alternative treatment therapies for cancer
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immune Checkpoint Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. CTLA-4 Inhibitor
  • 6.3. PD-1 Inhibitor
  • 6.4. PD-L1 Inhibitor

7. Immune Checkpoint Inhibitors Market, by Indication

  • 7.1. Introduction
  • 7.2. Bladder Cancer
  • 7.3. Breast Cancer
  • 7.4. Cervical Cancer
  • 7.5. Hodgkin Lymphoma
  • 7.6. Kidney Cancer
  • 7.7. Liver Cancer
  • 7.8. Lung Cancer
  • 7.9. Solid Cancer

8. Immune Checkpoint Inhibitors Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Immune Checkpoint Inhibitors Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Immune Checkpoint Inhibitors Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Immune Checkpoint Inhibitors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Immune Checkpoint Inhibitors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alphamab Oncolog
  • 2. ALX Oncology Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioNTech SE
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. F. Hoffmann-La Roche AG
  • 12. Genmab A/S
  • 13. GlaxoSmithKline PLC
  • 14. ImmuneSensor Therapeutics Inc.
  • 15. ImmunityBio, Inc.
  • 16. Kintor Pharmaceutical Limited
  • 17. Merck KGaA
  • 18. MiNK Therapeutics, Inc.
  • 19. NATCO Pharma Ltd.
  • 20. NextCure, Inc.
  • 21. Regeneron Pharmaceuticals Inc.
  • 22. Sanofi SA
  • 23. Seagen Inc.
  • 24. SQZ Biotechnologies Company
  • 25. Thermo Fisher Scientific Inc.
  • 26. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. IMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNE CHECKPOINT INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SOLID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023